全文获取类型
收费全文 | 31708篇 |
免费 | 2394篇 |
国内免费 | 94篇 |
学科分类
医药卫生 | 34196篇 |
出版年
2023年 | 104篇 |
2022年 | 83篇 |
2021年 | 450篇 |
2020年 | 257篇 |
2019年 | 444篇 |
2018年 | 574篇 |
2017年 | 418篇 |
2016年 | 487篇 |
2015年 | 552篇 |
2014年 | 846篇 |
2013年 | 1333篇 |
2012年 | 2042篇 |
2011年 | 2172篇 |
2010年 | 1161篇 |
2009年 | 1105篇 |
2008年 | 2065篇 |
2007年 | 2195篇 |
2006年 | 2170篇 |
2005年 | 2365篇 |
2004年 | 2093篇 |
2003年 | 1920篇 |
2002年 | 1944篇 |
2001年 | 346篇 |
2000年 | 275篇 |
1999年 | 345篇 |
1998年 | 423篇 |
1997年 | 402篇 |
1996年 | 373篇 |
1995年 | 361篇 |
1994年 | 291篇 |
1993年 | 277篇 |
1992年 | 238篇 |
1991年 | 259篇 |
1990年 | 238篇 |
1989年 | 214篇 |
1988年 | 187篇 |
1987年 | 209篇 |
1986年 | 173篇 |
1985年 | 187篇 |
1984年 | 234篇 |
1983年 | 225篇 |
1982年 | 275篇 |
1981年 | 269篇 |
1980年 | 224篇 |
1979年 | 132篇 |
1978年 | 149篇 |
1977年 | 97篇 |
1976年 | 122篇 |
1975年 | 84篇 |
1974年 | 110篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
Angelo Lipira David Limbrick Bruce Haughey Phillip Custer Michael R. Chicoine 《Skull base》2009,19(4):303-309
23.
25.
The role of the le fort I maxillotomy in the management of incompletely resected pituitary macroadenomas. 下载免费PDF全文
Objective: The options available for the treatment of a nonsecreting pituitary macroadenoma that has been incompletely resected include reoperation, fractionated radiation therapy, and radiosurgery. Reoperation in this setting may be hindered by the same obstacles that prevented a complete resection during the initial surgical procedure, and should prompt consideration of an alternate approach or exposure. Methods: Between January 1998 and December 2003, 10 consecutive patients were referred to the Department of Neurosurgery at the University of Texas Southwestern Medical Center for the evaluation of a nonsecreting pituitary macroadenoma that measured 3 cm or greater in diameter despite having undergone an attempt at a complete resection elsewhere. Each of these patients was reoperated using a Le Fort I maxillotomy to enhance the exposure provided by a traditional transsphenoidal approach. Results: A total or near total (> 95%) resection was achieved in each case. One patient required reoperation for the repositioning of a fat graft to treat a cerebrospinal fluid fistula and one patient experienced a worsening of anterior pituitary function postoperatively. Five patients noted improved vision and no patient experienced further visual loss. Three patients have required subsequent treatment of small foci of recurrent or progressing tumor with stereotactic radiation therapy. No patient has received fractionated radiation therapy. Conclusion: The added exposure provided by a Le Fort I maxillotomy facilitates the resection of pituitary macroadenomas that have been incompletely resected by a traditional transnasal, trans-sphenoidal approach. 相似文献
26.
Safety and efficacy of bariatric surgery: Longitudinal Assessment of Bariatric Surgery 总被引:3,自引:0,他引:3
Steven H. Belle Ph.D. M.Sc.Hyg. Paul D. Berk M.D. Anita P. Courcoulas M.D. M.P.H. F.A.C.S. David R. Flum M.D. M.P.H. F.A.C.S. Carolyn W. Miles Ph.D. James E. Mitchell M.D. Walter J. Pories M.D. F.A.C.S. Bruce M. Wolfe M.D. F.A.C.S. Susan Z. Yanovski M.D. Longitudinal Assessment of Bariatric Surgery Consortium Writing Group 《Surgery for obesity and related diseases》2007,3(2):116-126
27.
Hung-Fat Tse Sukumaran Thambar Yok-Lam Kwong Philip Rowlings Greg Bellamy Jane McCrohon Paul Thomas Bruce Bastian John K F Chan Gladys Lo Chi-Lai Ho Wing-Sze Chan Raymond Y Kwong Anthony Parker Thomas H Hauser Jenny Chan Daniel Y T Fong Chu-Pak Lau 《European heart journal》2007,28(24):2998-3005
AIMS: Experimental studies have demonstrated that bone marrow (BM) cells can induce angiogenesis in ischaemic myocardium. Recently, several non-randomized pilot studies have also suggested that direct BM cells implantation appears to be feasible and safe in patients with severe coronary artery diseases (CAD). METHODS AND RESULTS: We performed a randomized, blinded, and placebo-controlled trial in 28 CAD patients. After BM harvesting, we assigned patients to receive low dose (1 x 10(6) cells/0.1 mL, n = 9), high dose (2 x 10(6) cells/0.1 mL, n = 10) autologous BM cells or control (0.1 mL autologous plasma/injection, n = 9) catheter-based direct endomyocardial injection as guided by electromechanical mapping. Our primary endpoint was the increase in exercise treadmill time and our secondary endpoints were changes in Canadian Cardiovascular Society (CCS) and New York Heart Association (NYHA) class, and myocardial perfusion and left ventricular ejection fraction (LVEF) assessed by single-photon emission computed tomography and magnetic resonance imaging, respectively. A total 422 injections (mean 14.6 +/- 0.7 per patient) were successfully performed at 41 targeted ischaemic regions without any acute complication. Baseline exercise treadmill time was 439 +/- 182 s in controls and 393 +/- 136 s in BM-treated patients, and changed after 6 months to 383 +/- 223s and 464 +/- 196 s [BM treatment effect +0.43 log seconds (+53%), 95% CI 0.11-0.74, P = 0.014]. Compared with placebo injection, BM implantation was associated with a significant increase in LVEF (BM treatment effect +5.4%, 95% CI 0.4-10.3, P = 0.044) and a lower NYHA class (odds ratio for treatment effect 0.12, 95% CI 0.02-0.73, P = 0.021) after 6 months, but CCS reduced similarly in both groups. We observed no acute or long-term complications, including ventricular arrhythmia, myocardial damage, or development of intramyocardial tumour or calcification associated with BM implantation. CONCLUSION: Direct endomyocardial implantation of autologous BM cells significantly improved exercise time, LVEF, and NYHA functional class in patients with severe CAD who failed conventional therapy. 相似文献
28.
29.
Hillary R Bogner Mark S Cary Martha L Bruce Charles F Reynolds Benoit Mulsant Thomas Ten Have George S Alexopoulos 《The American journal of geriatric psychiatry》2005,13(10):861-868
OBJECTIVE: The authors described the influence of specific medical conditions on clinical remission and response of major depression (MDD) in a clinical trial evaluating a care-management intervention among older primary-care patients. METHODS: Adults age 60 years and older were randomly selected and screened for depression. Participants were randomly assigned to Usual Care or to an Intervention with a depression care-manager offering algorithm-based care for MDD. In all, 324 adults meeting criteria for MDD were included in these analyses. Remission and response was defined by a score on the Hamilton Rating Scale for Depression <10 and by a decrease from baseline of > or =50%, respectively. Medical comorbidity was ascertained through self-report. Cognitive impairment was defined by a score <24 on the Mini-Mental State Exam (MMSE). RESULTS: In Usual Care, rates of remission were faster in persons who reported atrial fibrillation (AF) than in persons who did not report AF and slower in persons who reported chronic pulmonary disease than in persons who did not report chronic pulmonary disease; rates of response were less stable in persons with MMSE <24 than in those with MMSE > or =24. In the Intervention condition, none of the specific chronic medical conditions were significantly associated with outcomes for MDD. CONCLUSIONS: Because disease-specific findings were observed in persons who received Usual Care but not in persons who received more intensive treatment in the Intervention condition, our results suggest that the association of medical comorbidity and treatment outcomes for MDD may be determined by the intensity of treatment for depression. 相似文献
30.
Robert M. Levy Roman Saikovsky Evgeniya Shmidt Alexander Khokhlov Bruce P. Burnett 《Nutrition Research》2009
Flavocoxid (Limbrel), a proprietary mixture of flavonoid molecules (baicalin and catechin), was tested against a traditional nonsteroidal anti-inflammatory drug, naproxen, for the management of the signs and symptoms of moderate osteoarthritis (OA) in humans. Discomfort and global disease activity were used as the primary end points, and safety assessments were also taken for both treatments as a secondary endpoint. In this double-blind study, 103 subjects were randomly assigned to receive either flavocoxid [500 mg twice daily (BID)] or naproxen (500 mg BID) in a 1-month onset of action trial. Outcome measures included the short Western Ontario and McMaster University Osteoarthritis Index, subject Visual Analogue Scale for discomfort and global response, and investigator Visual Analogue Scale for global response and fecal occult blood. Both flavocoxid and naproxen showed significant reduction in the signs and symptoms of knee OA (P ≤ .001). There were no statistically detectable differences between the flavocoxid and naproxen groups with respect to any of the outcome variables. Similarly, there were no statistically detectable differences between the groups with respect to any adverse event, although there was a trend toward a higher incidence of edema and nonspecific musculoskeletal discomfort in the naproxen group. In this short-term pilot study, flavocoxid was as effective as naproxen in controlling the signs and symptoms of OA of the knee and would present a safe and effective option for those individuals on traditional nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors. A low incidence of adverse events was reported for both groups. 相似文献